After Palantir's Impressive Earnings: The Big Stock Hurdle
Palantir’s latest quarter delivered impressive numbers, but the stock asks for more than strong growth. This guide br...
When Is Too Late To Start Retirement Planning
Understanding when it’s too late to start retirement planning is crucial for your financial health. Take action to secure your future now.
19,461 articlesIs UPS Stock a Bad-News Buy? A Pragmatic Turnaround Lens
When bad news hits a stock, investors ask if it’s a bargain. This piece weighs UPS’s challenges against its resilient...
Should Investors Cerebras Stock After Monster IPO Debut
Cerebras burst onto the public market with a splashy IPO, but a strong first day doesn’t guarantee long-term gains. T...
Opinion: SpaceX Stock Will Spark a Rally, Then Fade Fast
SpaceX stock will likely jump out of the gate on hype and AI buzz, but real-world risks could trim gains within weeks...
Madrigal (MDGL) 2025 Earnings: What Investors Should Know
As Madrigal prepares to report its 2025 earnings, investors weigh pipeline progress, cash runway, and milestones ahea...
Cumberland (CPIX) 2025 Earnings Outlook for Investors
Cumberland's 2025 earnings signal steady growth and improving margins, with a diversified product mix and a promising...
Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
This 6.5%-Yielding Dividend Payer Finds Fresh Ground
A high-yielding dividend payer is drawing attention as volatility grips markets. The company blends dependable income...
Scrolling UBI: Deloitte’s Fastest-Growing Software Firm Draws Investment
A Deloitte-recognized fastest-growing software firm opens the last phase of a pre-IPO funding round, offering micro-s...
Bitcoin’s ‘Most Emotional’ Bear Market Begins, Analyst Warns
A veteran analyst says bitcoin has slipped into its bitcoin’s ‘most emotional’ bear phase, setting up wild swings and...
Wall Street Analyst Thinks Viking Stock Could Soar 188%
A wall street analyst thinks Viking Therapeutics could unlock substantial upside if VK2735 delivers in Phase 3. Learn...
Here's Vertex Willing Premium: Inside the Crinetics Deal
When a pharma giant pays more than double a target’s value, the move sends shockwaves through investors. This article...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status